Evidence map›Paper›PMID 39352019›Full record

ArticleCA: a cancer journal for clinicians

Breast cancer: The good, the bad, and an important call to effective risk reduction strategies.

Virginia G Kaklamani, Carlos L Arteaga

Abstract readEditorial
In one paragraph

Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Cardiotoxicity in breast cancer patients treated with chemoradiotherapy.Exploration of targeted anti-tumor therapy · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Virginia G KaklamaniMays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA.ORCID https://orcid.org/0000-0002-3313-8458
Carlos L ArteagaSimmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, Texas, USA.

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancersR01CA277498 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Manjeet Kumar Rao · 2023 to 2026
$1.9M
Role of HER2 mutations in breast cancer progression and response to targeted therapiesR01CA224899 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ARTEAGA, CARLOS L · 2018 to 2022
$1.8M
Breast Cancer Research Foundation DRC-20-001Cancer Prevention and Research Institute of Texas RR170061NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA224899NCI NIH HHS R01CA224899NCI NIH HHS R01 CA277498NCI NIH HHS R01CA277498-02Susan G. Komen SAB1800010
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39352019
PMCPMC11560698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.